Result of AGM

RNS Number : 1329C

e-Therapeutics plc

16 June 2021

 

16 June 2021

e-therapeutics plc

Results of Annual General Meeting

Issue of Equity and Total Voting Rights

e-therapeutics plc   (AIM: ETX.L, "e-therapeutics'" or "the Company") is pleased to announce that all resolutions were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.

Results of the voting on each resolution will shortly be available on the Company's website at www.etherapeutics.co.uk.

Accordingly, pursuant to the Fundraise announced on 14 May 2021, an application has been made for, in aggregate, 93,750,000 new Ordinary Shares to be admitted to trading on AIM which is expected to occur at 8.00 a.m. on 17 June 2021.  The new Ordinary Shares comprise 81,208,333 Placing Shares, 8,708,334 Subscription Shares and 3,833,333 Retail Shares.

Total Voting Rights

Following the issue of the Placing Shares, Subscription Shares and Retail Shares, the Company will have 514,523,546   Ordinary Shares of 0.1 pence each in issue.  T he Company does not hold any Ordinary Shares in treasury.  The figure of 514,523,546 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Defined terms in this announcement shall have the same meaning as in the Launch Announcement dated 13 May 2021 unless otherwise specified.

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO Karl Keegan, CFO	Tel: [phone]  www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

 

END

 

 

RAGUNUURANUNAAR